Royalty Pharma plc
RPRX
Clasificación en acciones
#899
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Precio por acción
$60.09
Capitalización bursátil
$26.75B
Cambio (1 día)
-1.44%
Cambio (1 año)
62.35%
País
US
Comercio Royalty Pharma plc (RPRX)
Categoría
Healthcare
EPS de Royalty Pharma plc (RPRX)
EPS a fecha de June 2026 TTM: $2.41
Según los últimos informes financieros y el precio de las acciones de Royalty Pharma plc, el EPS actual de la empresa (TTM) es $2.41. Al final del año 2024, la empresa tenía un EPS de $1.92 una disminución en comparación con al EPS de 2023, que fue de $2.54.
Historial de EPS de Royalty Pharma plc desde 2015 hasta 2026
EPS al final de cada año
| Año | EPS | Cambiar |
|---|---|---|
| 2026 (TTM) | $2.41 | 34.64% |
| 2025 | $1.79 | -6.61% |
| 2024 | $1.92 | -24.41% |
| 2023 | $2.54 | 2,492.43% |
| 2022 | $0.10 | -93.45% |
| 2021 | $1.49 | -42.47% |
| 2020 | $2.60 | -59.54% |
| 2019 | $6.42 | 182.80% |
| 2018 | $2.27 | 13.86% |
| 2017 | $1.99 | 113.83% |
| 2016 | $0.93 | -2.67% |
| 2015 | $0.96 | 0.00% |
EPS de empresas similares o competidoras
| Empresa | EPS | Diferencia de EPS | País |
|---|---|---|---|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.52 | -78.42% |
US
|
|
| $0.02 | -99.22% |
HK
|
